163 related articles for article (PubMed ID: 29759563)
1. Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.
Cai Y; Feng L; Wang X
Crit Rev Oncol Hematol; 2018 Jun; 126():24-31. PubMed ID: 29759563
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
Vaisitti T; Arruga F; Deaglio S
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29649100
[TBL] [Abstract][Full Text] [Related]
3. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
4. CD38 and chronic lymphocytic leukemia: a decade later.
Malavasi F; Deaglio S; Damle R; Cutrona G; Ferrarini M; Chiorazzi N
Blood; 2011 Sep; 118(13):3470-8. PubMed ID: 21765022
[TBL] [Abstract][Full Text] [Related]
5. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.
Sutton LA; Rosenquist R
Semin Cancer Biol; 2015 Oct; 34():22-35. PubMed ID: 25963298
[TBL] [Abstract][Full Text] [Related]
6. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia (CLL): a model for understanding and treating chronic B-cell malignancies.
Caligaris-Cappio F
Rinsho Ketsueki; 2013 Oct; 54(10):1838-42. PubMed ID: 24064834
[No Abstract] [Full Text] [Related]
8. Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Del Poeta G; Gaidano G; Rossi FM; Zucchetto A; Gattei V
Semin Hematol; 2014 Jul; 51(3):168-76. PubMed ID: 25048781
[TBL] [Abstract][Full Text] [Related]
9. LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Nguyen PH; Fedorchenko O; Rosen N; Koch M; Barthel R; Winarski T; Florin A; Wunderlich FT; Reinart N; Hallek M
Cancer Cell; 2016 Oct; 30(4):610-622. PubMed ID: 27728807
[TBL] [Abstract][Full Text] [Related]
10. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
Crassini K; Shen Y; Mulligan S; Giles Best O
Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
[TBL] [Abstract][Full Text] [Related]
11. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
13. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis of chronic lymphocytic leukemia].
Fukuda T
Rinsho Ketsueki; 2015 Mar; 56(3):261-8. PubMed ID: 25876778
[TBL] [Abstract][Full Text] [Related]
15. SnapShot: Chronic Lymphocytic Leukemia.
Ten Hacken E; Guièze R; Wu CJ
Cancer Cell; 2017 Nov; 32(5):716-716.e1. PubMed ID: 29136511
[TBL] [Abstract][Full Text] [Related]
16. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia.
Alsagaby SA; Alhumaydhi FA
Saudi Med J; 2019 Apr; 40(4):317-327. PubMed ID: 30957124
[TBL] [Abstract][Full Text] [Related]
17. A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.
Farinello D; Wozińska M; Lenti E; Genovese L; Bianchessi S; Migliori E; Sacchetti N; di Lillo A; Bertilaccio MTS; de Lalla C; Valsecchi R; Gleave SB; Lligé D; Scielzo C; Mauri L; Ciampa MG; Scarfò L; Bernardi R; Lazarevic D; Gonzalez-Farre B; Bongiovanni L; Campo E; Cerutti A; Ponzoni M; Pattini L; Caligaris-Cappio F; Ghia P; Brendolan A
Nat Commun; 2018 May; 9(1):1787. PubMed ID: 29725010
[TBL] [Abstract][Full Text] [Related]
18. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.
Seiffert M; Dietrich S; Jethwa A; Glimm H; Lichter P; Zenz T
Leuk Lymphoma; 2012 Jun; 53(6):1023-31. PubMed ID: 22023519
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression.
Vaupel P; Mayer A
Adv Exp Med Biol; 2016; 876():177-183. PubMed ID: 26782210
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
